In the AtezoTRIBE randomized phase II trial, the addition of atezolizumab to the FOLFOXIRI plus bevacizumab regimen improved outcomes in immune-enriched molecular subsets, suggesting that transient cytotoxic debulking coupled with VEGF blockade may transiently remodel the tumor microenvironment, promoting immune recognition and infiltration [224]. The gene discussed is VEGFA; the disease is neoplasm.